These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32784089)

  • 21. Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays.
    Parodi A; Righetti G; Pesce E; Salis A; Tasso B; Urbinati C; Tomati V; Damonte G; Rusnati M; Pedemonte N; Cichero E; Millo E
    Eur J Med Chem; 2020 Dec; 208():112833. PubMed ID: 32971410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
    Birault V; Solari R; Hanrahan J; Thomas DY
    Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation.
    Pasyk S; Molinski S; Ahmadi S; Ramjeesingh M; Huan LJ; Chin S; Du K; Yeger H; Taylor P; Moran MF; Bear CE
    Proteomics; 2015 Jan; 15(2-3):447-61. PubMed ID: 25330774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
    Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
    Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
    Lin S; Sui J; Cotard S; Fung B; Andersen J; Zhu P; El Messadi N; Lehar J; Lee M; Staunton J
    Assay Drug Dev Technol; 2010 Dec; 8(6):669-84. PubMed ID: 21050065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The search for a common structural moiety among selected pharmacological correctors of the mutant CFTR chloride channel.
    Nieddu E; Pollarolo B; Mazzei MT; Anzaldi M; Schenone S; Pedemonte N; Pesce E; Galietta LJ; Mazzei M
    Future Med Chem; 2014; 6(17):1857-68. PubMed ID: 25495980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis.
    Mijnders M; Kleizen B; Braakman I
    Curr Opin Pharmacol; 2017 Jun; 34():83-90. PubMed ID: 29055231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR.
    Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN
    Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations.
    Pedemonte N; Tomati V; Sondo E; Caci E; Millo E; Armirotti A; Damonte G; Zegarra-Moran O; Galietta LJ
    J Biol Chem; 2011 Apr; 286(17):15215-26. PubMed ID: 21383017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
    Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent Progress in the Discovery and Development of Small-Molecule Modulators of CFTR.
    Kym PR; Wang X; Pizzonero M; Van der Plas SE
    Prog Med Chem; 2018; 57(1):235-276. PubMed ID: 29680149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corrector combination therapies for F508del-CFTR.
    Hanrahan JW; Matthes E; Carlile G; Thomas DY
    Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives.
    Brusa I; Sondo E; Falchi F; Pedemonte N; Roberti M; Cavalli A
    J Med Chem; 2022 Apr; 65(7):5212-5243. PubMed ID: 35377645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR.
    Moniz S; Sousa M; Moraes BJ; Mendes AI; Palma M; Barreto C; Fragata JI; Amaral MD; Matos P
    ACS Chem Biol; 2013 Feb; 8(2):432-42. PubMed ID: 23148778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids.
    Dekkers JF; Gogorza Gondra RA; Kruisselbrink E; Vonk AM; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
    Eur Respir J; 2016 Aug; 48(2):451-8. PubMed ID: 27103391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenylhydrazones as Correctors of a Mutant Cystic Fibrosis Transmembrane Conductance Regulator.
    Nieddu E; Pollarolo B; Mazzei MT; Anzaldi M; Schenone S; Pedemonte N; Galietta LJ; Mazzei M
    Arch Pharm (Weinheim); 2016 Feb; 349(2):112-23. PubMed ID: 26701662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.
    Phuan PW; Son JH; Tan JA; Li C; Musante I; Zlock L; Nielson DW; Finkbeiner WE; Kurth MJ; Galietta LJ; Haggie PM; Verkman AS
    J Cyst Fibros; 2018 Sep; 17(5):595-606. PubMed ID: 29903467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis.
    Donald MB; Rodriguez KX; Shay H; Phuan PW; Verkman AS; Kurth MJ
    Bioorg Med Chem; 2012 Sep; 20(17):5247-53. PubMed ID: 22841006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.